Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 30, 2017 in Melanoma | 0 comments

In a nutshell

This study investigated the secondary effects of having axillary lymphadenectomy (ALD; surgery to remove the lymph nodes in the underarms region) in melanoma patients. Researchers suggested that ALD is a low risk surgery for melanoma patients.

Some background

The standard treatment for melanoma patients spread to the lymph nodes is surgery. It is known that this surgery is associated with negative side effects. However, ADL side effects are not well known. In addition to that, a prior study suggested that the removal of lymph nodes is not associated with increased survival in patients with melanoma that has spread. The benefit of this surgery and risk factors of each patient should be considered by clinicians for an adequate treatment. 

Methods & findings

This study aimed to investigate the post-ADL side effects in patients with melanoma spread to the lymph nodes.

This study included 239 patients who underwent ALD. Complications were measured for 60 days after surgery. Lymphedema (swelling of the lymph nodes) was measured 2 weeks, 6 weeks and 3 months after surgery. Patients were then followed every 4 months for 3 years, every 6 months until year 5 and then every year until year 10.

Some factors were associated with an increased risk of negative side effects after surgery. These factors included being 55 years of age or older (52%), increased body weight (40%), diabetes (16%), smoking (32%) and lymphadenectomy (41%).

Wound complications were seen in 51 patients. These included dehiscence (splitting of a wound or organ) in 3 patients and hematomas (clotted blood caused by a broken blood vessel) in 10 patients. 

The bottom line

This study determined that the ALD is a low risk procedure with manageable side effects.  

Published By :

Annals of Surgical Oncology

Date :

Nov 20, 2017

Original Title :

Morbidity and Outcomes Following Axillary Lymphadenectomy for Melanoma: Weighing the Risk of Surgery in the Era of MSLT-II.

click here to get personalized updates